A Phase 1/2 interventional study of clofarabine and Etoposide in Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia and Relapsed Leukemia, sponsored by Genzyme, a Sanofi Company. Completed at 13 sites in United States. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2014-04-14.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing clofarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 3 open to participants now, 4 under way, 1 of them phase 3. Clofarabine · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 55 studies testing clofarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 18th largest by enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2006, is one of 10 in phase 1/2, and was the 6th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →3 of the 55 studies testing clofarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
M.D. Anderson Cancer Center · Sites in United States
Ages 15+
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Clofarabine: first FDA approval 2004 (CLOLAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 1 Year to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 36 · Phase 3 3
First in 2002; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 35 across the 54 interventional studies. Of the 50 that completed or were terminated, 25 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi: none open now, none under way, none of them phase 3. Of 11 finished, 3 (27%) have results posted.
Among the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2006, is one of 2 in phase 1/2, and was the 5th registered.
Sanofi’s Precursor Cell Lymphoblastic Leukemia-Lymphoma studies by the year they started, since 1997.
2 of the studies testing clofarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
| NCT03136146M.D. Anderson Cancer CenterCombination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 55 studies testing clofarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Among Sanofi’s 11 in Precursor Cell Lymphoblastic Leukemia-Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted.
The purpose of the phase 1 portion of this study was to determine if clofarabine added to a combination of etoposide and cyclophosphamide is safe in children with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). The purpose of the phase 2 portion of the study was to measure the effectiveness of the combination therapy in children with ALL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m\^2, etoposide dosage from 75-100 mg/m\^2, cyclophosphamide dosage from 340-440 mg/m\^2. Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m\^2, etoposide 100 mg/m\^2 and cyclophosphamide 440 mg/m\^2 delivered intravenously
Drug: clofarabine · Drug: Etoposide · Drug: Cyclophosphamide
Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
Also known as: Clolar, Evoltra
Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
Also known as: Eposin
Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
Also known as: Endoxan, Revimmune, Cytoxan
Maximum Tolerated Dose (MTD) in Phase 1
The MTD was to be the highest dose level of clofarabine in combination with etoposide and cyclophosphamide that caused \<= 1 of 6 participants to experience a dose limiting toxicity (DLT) with the next higher dose level having at least 2 of 3 or 2 of 6 participants experiencing a DLT. The MTD would be used as the recommended phase 2 dose (RP2D). If the MTD could not be determined, then the target dose of clofarabine 40 mg/m\^2, etoposide 100 mg/m\^2 and cyclophosphamide 440 mg/m\^2 as taken by Cohort 5 was to become the RP2D. The rating scale used is 0 = not the MTD, 1 = the MTD.
Time frame: Up to Day 42 (Phase 1 portion of study)
Participants With Dose Limiting Toxicity in Phase 1
The number of participants in each cohort that had dose limiting toxicity is summarized. Toxicities were reviewed by an independent Data Safety Monitoring Board (DSMB) who determined if additional participants should be added to the cohort and the criteria for escalating to the next cohort.
Time frame: Up to Day 42 (Phase 1 portion of study)
Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 2
Response categories 1) complete remission (CR): without circulating blasts or extramedullary disease, bone marrow (BM) with \<5% blasts, and platelet (plt)/ANC recovery: ≥75/ ≥0.75 \[x 10\^9/L\] 2) CR in absence of plt recovery (CRp): plt ≥20 to \<75 x 10\^9/L 3) partial remission (PR): no circulating blasts, appearance of normal hematopoietic progenitors, and either a BM with ≥5% and ≤25% blasts with recovery of plts/ANC or a BM with \<5% blasts not meeting CR/CRp definition 4) Overall remission (OR): CR+CRp 5) Any response: CR+CRp+PR.
Time frame: Approximately 28-56 days (Phase 2 portion of study)
Summary of Participants With Adverse Events (AEs) in Phase 1
Number of participants with AEs that occurred during treatment and follow-up period (45 days after last cycle). Drug-related AEs and SAEs were followed until resolved or mutually agreed by the investigator and Genzyme to discontinue reporting. AEs were classified by the investigator according to severity (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0) and relationship to study drug. The severity scale is:\> Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death related to AE
Time frame: Up to 9.5 months (Phase 1 portion of study)
Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 1
Response categories 1) complete remission (CR): without circulating blasts or extramedullary disease, bone marrow (BM) with \<5% blasts, and platelet (plt)/ANC recovery: ALL ≥75/ ≥0.75 \[x 10\^9/L\]; AML ≥100/ ≥1.0 \[x 10\^9/L\] 2) CR in absence of plt recovery (CRp): ALL plt ≥20 to \<75 x 10\^9/L; AML plt ≥20 to \<100 x 10\^9/L 3) partial remission (PR): no circulating blasts, appearance of normal hematopoietic progenitors, and either a BM with ≥5% and ≤25% blasts with recovery of plts/ANC or a BM with \<5% blasts not meeting CR/CRp definition 4) Overall remission (OR): CR+CRp 5) Any response: CR+CRp+PR.
Time frame: Approximately 2 months (Phase 1 portion of study)
Time to Remission for Participants Who Had a Response in Phase 1
The weeks between start of intervention and remission as assessed by the investigator in Phase 1. Participants who had a complete remission (CR) or complete remission with the absence of total platelet recovery (CRp) are included.
Time frame: up to 8 weeks (Phase 1 portion of study)
Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 1
Duration of response is the time from the first objective measurement of complete response (CR) or complete response with the absence of total platelet recovery (CRp) to the date of first objective documentation of disease relapse or death due to any cause, plus one day. For summary purposes, results are presented as weeks.
Time frame: Up to 2 years (Phase 1 portion of study)
Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 1
Event-free survival (EFS) is defined as the time from date of first administration of study interventions until the earliest of the following: date of death or date of first response assessment confirming relapse or date of final response assessment which fails to confirm response, plus one day. For summary purposes, results are presented as weeks.
Time frame: Up to 2 years (Phase 1 portion of study)
Number of Participants With 4-month Event Free Survival in Phase 1
Number of participants with event-free survival at four months post first dose of therapy. A participant is considered event-free if at month 4 they have not died or had a response assessment confirming a relapse.
Time frame: 4 months (Phase I portion of study)
Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 1
Overall survival is defined as the time from date of first administration of study interventions until date of death, plus one day. For summary purposes, results are presented as weeks.
Time frame: Up to 2 years (Phase 1 portion of study)
Summary of Participants With Adverse Events (AEs) in Phase 2
Number of participants with AEs that occurred during treatment and follow-up period (45 days after last cycle). Drug-related AEs and SAEs were followed until resolved or mutually agreed by the investigator and Genzyme to discontinue reporting. AEs were classified by the investigator according to severity (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0) and relationship to study drug. The severity scale is:\> Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death related to AE
Time frame: Up to 9.5 months (Phase 2 portion of study)
Time to Remission for Participants Who Had a Response in Phase 2
The weeks between start of intervention and remission as assessed by the investigator in Phase 2. Participants who had a complete remission (CR) or complete remission with the absence of total platelet recovery (CRp) are included.
Time frame: up to 8 weeks (Phase 2 portion of study)
Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 2
Duration of response is the time from the first objective measurement of complete response (CR) or complete response with the absence of total platelet recovery (CRp) to the date of first objective documentation of disease relapse or death due to any cause, plus one day. For summary purposes, results are presented as weeks.
Time frame: Up to 2 years (Phase 2 portion of study)
Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 2
Event-free survival (EFS) is defined as the time from date of first administration of study interventions until the earliest of the following: date of death or date of first response assessment confirming relapse or date of final response assessment which fails to confirm response, plus one day. For summary purposes, results are presented as weeks.
Time frame: Up to 2 years (Phase 2 portion of study)
Number of Participants With 4-month Event Free Survival in Phase 2
Number of participants with event-free survival at four months post first dose of therapy. A participant is considered event-free if at month 4 they have not died or had a response assessment confirming a relapse.
Time frame: 4 months (Phase 2 portion of study)
Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 2
Overall survival is defined as the time from date of first administration of study interventions until date of death, plus one day. For summary purposes, results are presented as weeks.
Time frame: Up to 2 years (Phase 2 portion of study)
| Milestone | Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Started | 25 |
| Completed | 0 |
| Not completed | 25 |
| Withdrew: Refused further treatment | 1 |
| Withdrew: Failure to achieve response | 8 |
| Withdrew: Disease relapse | 4 |
| Withdrew: Scheduled for transplant | 9 |
| Withdrew: Death | 3 |
| Milestone | Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Started | 25 |
| Completed | 0 |
| Not completed | 25 |
| Withdrew: Physician decision | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Failure to achieve response | 3 |
| Withdrew: Disease relapse | 1 |
| Withdrew: Scheduled for transplant | 8 |
| Withdrew: Other | 1 |
| Withdrew: Death | 7 |
The MTD was to be the highest dose level of clofarabine in combination with etoposide and cyclophosphamide that caused \<= 1 of 6 participants to experience a dose limiting toxicity (DLT) with the next higher dose level having at least 2 of 3 or 2 of 6 participants experiencing a DLT. The MTD would be used as the recommended phase 2 dose (RP2D). If the MTD could not be determined, then the target dose of clofarabine 40 mg/m\^2, etoposide 100 mg/m\^2 and cyclophosphamide 440 mg/m\^2 as taken by Cohort 5 was to become the RP2D. The rating scale used is 0 = not the MTD, 1 = the MTD.
| units on a scale | Phase 1 - Cohort 1 | Phase 1 - Cohort 2 | Phase 1 - Cohort 3 | Phase 1 - Cohort 4 | Phase 1 - Cohort 5 |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) in Phase 1 | 0 | 0 | 0 | 0 | 0 |
The number of participants in each cohort that had dose limiting toxicity is summarized. Toxicities were reviewed by an independent Data Safety Monitoring Board (DSMB) who determined if additional participants should be added to the cohort and the criteria for escalating to the next cohort.
| participants | Phase 1 - Cohort 1 | Phase 1 - Cohort 2 | Phase 1 - Cohort 3 | Phase 1 - Cohort 4 | Phase 1 - Cohort 5 |
|---|---|---|---|---|---|
| Participants With Dose Limiting Toxicity in Phase 1 | 0 | 0 | 0 | 1 | 1 |
Number of participants with AEs that occurred during treatment and follow-up period (45 days after last cycle). Drug-related AEs and SAEs were followed until resolved or mutually agreed by the investigator and Genzyme to discontinue reporting. AEs were classified by the investigator according to severity (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0) and relationship to study drug. The severity scale is:\> Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death related to AE
| participants | Phase 1 - Cohort 1 | Phase 1 - Cohort 2 | Phase 1 - Cohort 3 | Phase 1 - Cohort 4 | Phase 1 - Cohort 5 |
|---|---|---|---|---|---|
| At least one AE | 3 | 3 | 3 | 10 | 6 |
| At least one AE related to clofarabine | 3 | 3 | 3 | 10 | 6 |
| At least one serious AE | 3 | 3 | 3 | 9 | 6 |
| At least one serious AE related to clofarabine | 3 | 2 | 3 | 9 | 5 |
| Discontinued study due to AE | 0 | 0 | 0 | 0 | 0 |
| Died | 3 | 1 | 3 | 9 | 5 |
| AE with the worst grade of: 1 | 0 | 0 | 0 | 0 | 0 |
| AE with the worst grade of: 2 | 0 | 0 | 0 | 0 | 0 |
| AE with the worst grade of: 3 | 2 | 1 | 1 | 3 | 3 |
| AE with the worst grade of: 4 | 1 | 1 | 2 | 5 | 2 |
| AE with the worst grade of: 5 | 0 | 1 | 0 | 2 | 1 |
Response categories 1) complete remission (CR): without circulating blasts or extramedullary disease, bone marrow (BM) with \<5% blasts, and platelet (plt)/ANC recovery: ALL ≥75/ ≥0.75 \[x 10\^9/L\]; AML ≥100/ ≥1.0 \[x 10\^9/L\] 2) CR in absence of plt recovery (CRp): ALL plt ≥20 to \<75 x 10\^9/L; AML plt ≥20 to \<100 x 10\^9/L 3) partial remission (PR): no circulating blasts, appearance of normal hematopoietic progenitors, and either a BM with ≥5% and ≤25% blasts with recovery of plts/ANC or a BM with \<5% blasts not meeting CR/CRp definition 4) Overall remission (OR): CR+CRp 5) Any response: CR+CRp+PR.
| percentage of total participants | Phase 1: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Complete remission (CR) | 40 |
| Complete remission/absence total platelet recovery | 24 |
| Partial remission (PR) | 0 |
| Overall remission (OR) | 64 |
| Any response (CR+CRp+PR) | 64 |
The weeks between start of intervention and remission as assessed by the investigator in Phase 1. Participants who had a complete remission (CR) or complete remission with the absence of total platelet recovery (CRp) are included.
| weeks | Phase 1: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Time to Remission for Participants Who Had a Response in Phase 1 | 4.96 ± 1.912 |
Duration of response is the time from the first objective measurement of complete response (CR) or complete response with the absence of total platelet recovery (CRp) to the date of first objective documentation of disease relapse or death due to any cause, plus one day. For summary purposes, results are presented as weeks.
| weeks | Phase 1: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 1 | 18.2 (12.9 to 35.0) |
Event-free survival (EFS) is defined as the time from date of first administration of study interventions until the earliest of the following: date of death or date of first response assessment confirming relapse or date of final response assessment which fails to confirm response, plus one day. For summary purposes, results are presented as weeks.
| weeks | Phase 1: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 1 | 19.3 (12.7 to 27.1) |
Number of participants with event-free survival at four months post first dose of therapy. A participant is considered event-free if at month 4 they have not died or had a response assessment confirming a relapse.
| participants | Phase 1: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Number of Participants With 4-month Event Free Survival in Phase 1 | 13 |
Overall survival is defined as the time from date of first administration of study interventions until date of death, plus one day. For summary purposes, results are presented as weeks.
| weeks | Phase 1: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 1 | 27.1 (18.3 to 42.9) |
Response categories 1) complete remission (CR): without circulating blasts or extramedullary disease, bone marrow (BM) with \<5% blasts, and platelet (plt)/ANC recovery: ≥75/ ≥0.75 \[x 10\^9/L\] 2) CR in absence of plt recovery (CRp): plt ≥20 to \<75 x 10\^9/L 3) partial remission (PR): no circulating blasts, appearance of normal hematopoietic progenitors, and either a BM with ≥5% and ≤25% blasts with recovery of plts/ANC or a BM with \<5% blasts not meeting CR/CRp definition 4) Overall remission (OR): CR+CRp 5) Any response: CR+CRp+PR.
| percentage of total participants | Phase 2: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Complete remission (CR) | 28 |
| Complete remission/absence total platelet recovery | 16 |
| Partial remission (PR) | 12 |
| Overall remission (OR) | 44 |
| Any response (CR+CRp+PR) | 56 |
Number of participants with AEs that occurred during treatment and follow-up period (45 days after last cycle). Drug-related AEs and SAEs were followed until resolved or mutually agreed by the investigator and Genzyme to discontinue reporting. AEs were classified by the investigator according to severity (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0) and relationship to study drug. The severity scale is:\> Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death related to AE
| participants | Phase 2: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| At least one AE | 25 |
| At least one AE related to clofarabine | 25 |
| At least one serious AE | 21 |
| At least one serious AE related to clofarabine | 20 |
| Discontinued study due to AE | 1 |
| Died | 16 |
| AE with the worst grade of: 1 | 0 |
| AE with the worst grade of: 2 | 0 |
| AE with the worst grade of: 3 | 1 |
| AE with the worst grade of: 4 | 16 |
| AE with the worst grade of: 5 | 8 |
The weeks between start of intervention and remission as assessed by the investigator in Phase 2. Participants who had a complete remission (CR) or complete remission with the absence of total platelet recovery (CRp) are included.
| weeks | Phase 2: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Time to Remission for Participants Who Had a Response in Phase 2 | 4.84 ± 2.092 |
Duration of response is the time from the first objective measurement of complete response (CR) or complete response with the absence of total platelet recovery (CRp) to the date of first objective documentation of disease relapse or death due to any cause, plus one day. For summary purposes, results are presented as weeks.
| weeks | Phase 2: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 2 | 67.3 (13.4 to NA) |
Event-free survival (EFS) is defined as the time from date of first administration of study interventions until the earliest of the following: date of death or date of first response assessment confirming relapse or date of final response assessment which fails to confirm response, plus one day. For summary purposes, results are presented as weeks.
| weeks | Phase 2: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 2 | 10.7 (6.7 to 73.9) |
Number of participants with event-free survival at four months post first dose of therapy. A participant is considered event-free if at month 4 they have not died or had a response assessment confirming a relapse.
| participants | Phase 2: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Number of Participants With 4-month Event Free Survival in Phase 2 | 11 |
Overall survival is defined as the time from date of first administration of study interventions until date of death, plus one day. For summary purposes, results are presented as weeks.
| weeks | Phase 2: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|
| Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 2 | 10.7 (8.1 to 38.6) |
Collected over Treatment emergent adverse experiences collected in Phase 1 from day 1 up to 9.5 months. Phase 2 also lasted up to 9.5 months and started after Phase 1.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 - Cohort 1 | — | 3/3 (100%) | 3/3 (100%) |
| Phase 1 - Cohort 2 | — | 3/3 (100%) | 3/3 (100%) |
| Phase 1 - Cohort 3 | — | 3/3 (100%) | 3/3 (100%) |
| Phase 1 - Cohort 4 | — | 9/10 (90%) | 10/10 (100%) |
| Phase 1 - Cohort 5 | — | 6/6 (100%) | 6/6 (100%) |
| Phase 1 - Total | — | 24/25 (96%) | 25/25 (100%) |
| Phase 2: Clofarabine, Etoposide, Cyclophosphamide | — | 21/25 (84%) | 25/25 (100%) |
| Event | Phase 1 - Cohort 1 | Phase 1 - Cohort 2 | Phase 1 - Cohort 3 | Phase 1 - Cohort 4 | Phase 1 - Cohort 5 | Phase 1 - Total | Phase 2: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/3 | 1/3 | 3/3 | 7/10 | 3/6 | 17/25 | 15/25 |
| PyrexiaGeneral disorders | 1/3 | 0/3 | 3/3 | 2/10 | 0/6 | 6/25 | 3/25 |
| NeutropeniaBlood and lymphatic system disorders | 1/3 | 0/3 | 1/3 | 1/10 | 2/6 | 5/25 | 0/25 |
| TrichiasisEye disorders | 0/3 | 0/3 | 1/3 | 0/10 | 0/6 | 1/25 | 0/25 |
| Abdominal painGastrointestinal disorders | 0/3 | 1/3 | 0/3 | 1/10 | 0/6 | 2/25 | 1/25 |
| AscitesGastrointestinal disorders | 0/3 | 1/3 | 0/3 | 0/10 | 0/6 | 1/25 | 0/25 |
| CaecitisGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 3/10 | 0/6 | 4/25 | 3/25 |
| Rectal fissureGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 0/10 | 0/6 | 1/25 | 0/25 |
| Generalised oedemaGeneral disorders | 0/3 | 1/3 | 0/3 | 0/10 | 0/6 | 1/25 | 0/25 |
| Drug hypersensitivityImmune system disorders | 0/3 | 1/3 | 0/3 | 0/10 | 0/6 | 1/25 | 0/25 |
| Event | Phase 1 - Cohort 1 | Phase 1 - Cohort 2 | Phase 1 - Cohort 3 | Phase 1 - Cohort 4 | Phase 1 - Cohort 5 | Phase 1 - Total | Phase 2: Clofarabine, Etoposide, Cyclophosphamide |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/3 | 2/3 | 3/3 | 9/10 | 5/6 | 21/25 | 20/25 |
| VomitingGastrointestinal disorders | 2/3 | 2/3 | 3/3 | 9/10 | 6/6 | 22/25 | 22/25 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 3/3 | 3/10 | 1/6 | 7/25 | 4/25 |
| Abdominal painGastrointestinal disorders | 1/3 | 0/3 | 1/3 | 9/10 | 2/6 | 13/25 | 7/25 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 2/3 | 1/3 | 7/10 | 5/6 | 17/25 | 7/25 |
| PyrexiaGeneral disorders | 2/3 | 0/3 | 1/3 | 7/10 | 5/6 | 15/25 | 13/25 |
| HeadacheNervous system disorders | 1/3 | 0/3 | 2/3 | 7/10 | 4/6 | 14/25 | 9/25 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 1/3 | 2/3 | 1/10 | 2/6 | 7/25 | 16/25 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/3 | 0/3 | 2/3 | 5/10 | 3/6 | 11/25 | 16/25 |
| Ear painEar and labyrinth disorders | 0/3 | 0/3 | 2/3 | 1/10 | 1/6 | 4/25 | 0/25 |
| Age, Continuous(years) | Phase 1: Clofarabine, Etoposide, Cyclophosphamide | Phase 2: Clofarabine, Etoposide, Cyclophosphamide | Total |
|---|---|---|---|
| Mean | 9.1 ± 5.03 | 13.2 ± 5.25 | 11.2 ± 5.49 |
| Sex: Female, Male(Participants) | Phase 1: Clofarabine, Etoposide, Cyclophosphamide | Phase 2: Clofarabine, Etoposide, Cyclophosphamide | Total |
|---|---|---|---|
| Female | 10 | 9 | 19 |
| Male | 15 | 16 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Clofarabine, Etoposide, Cyclophosphamide | Phase 2: Clofarabine, Etoposide, Cyclophosphamide | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 10 | 15 |
| Not Hispanic or Latino | 20 | 15 | 35 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1: Clofarabine, Etoposide, Cyclophosphamide | Phase 2: Clofarabine, Etoposide, Cyclophosphamide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 16 | 12 | 28 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 8 | 10 |
| Percent Leukemic Blast Cells(percentage of total blast cells) | Phase 1: Clofarabine, Etoposide, Cyclophosphamide | Phase 2: Clofarabine, Etoposide, Cyclophosphamide | Total |
|---|---|---|---|
| Mean | 66.8 ± 24.85 | 69.52 ± 23.566 | 68.16 ± 24.008 |
| Absolute Neutrophil Counts(10^9/L) | Phase 1: Clofarabine, Etoposide, Cyclophosphamide | Phase 2: Clofarabine, Etoposide, Cyclophosphamide | Total |
|---|---|---|---|
| Mean | 1.93828 ± 3.049992 | 1.9280 ± 1.708126 | 1.93325 ± 2.459536 |
| White Blood Cell Counts(10^9/L) | Phase 1: Clofarabine, Etoposide, Cyclophosphamide | Phase 2: Clofarabine, Etoposide, Cyclophosphamide | Total |
|---|---|---|---|
| Mean | 8.323 ± 9.1305 | 12.171 ± 23.0150 | 10.247 ± 17.4370 |
| Immunophenotype(participants) | Phase 1: Clofarabine, Etoposide, Cyclophosphamide | Phase 2: Clofarabine, Etoposide, Cyclophosphamide | Total |
|---|---|---|---|
| B cell | 13 | 21 | 34 |
| T cell | 5 | 1 | 6 |
| Unknown | 2 | 3 | 5 |
| not included (AML participants) | 5 | 0 | 5 |
4 further baseline measures are reported on the registry.
The record gives a start of Mar 2006, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clofarabine · Etoposide · Cyclophosphamide
Precursor Cell Lymphoblastic Leukemia-Lymphoma →